Table 2.
Changes to index therapy: add-on treatment over 12 months according to index antidiabetic drug class in UT patients, n (%)
| JMDC database | |||||||||
| Index treatment | DPP-4i | BG | SU | α-GI | TZD | Glinide | SGLT2i | Insulin | GLP-1 |
| Pts with add-on therapy | n=2839 | n=1102 | n=364 | n=316 | n=102 | n=50 | n=76 | n=7 | n=8 |
| +DPP-4i | NA | 748 (67.9) | 208 (57.1) | 146 (46.2) | 57 (55.9) | 21 (42.0) | 34 (44.7) | 4 (57.1) | 1 (12.5) |
| +BG | 1324 (46.6) | NA | 80 (22.0) | 85 (26.9) | 21 (20.6) | 9 (18.0) | 28 (36.8) | 2 (28.6) | 1 (12.5) |
| +SU | 537 (18.9) | 66 (6.0) | NA | 30 (9.5) | 8 (7.8) | 1 (2.0) | 5 (6.6) | 0 (0.0) | 2 (25.0) |
| +α-GI | 255 (9.0) | 40 (3.6) | 25 (6.9) | NA | 4 (3.9) | 15 (30.0) | 5 (6.6) | 0 (0.0) | 0 (0.0) |
| +TZD | 293 (10.3) | 58 (5.3) | 20 (5.5) | 16 (5.1) | NA | 1 (2.0) | 1 (1.3) | 0 (0.0) | 2 (25.0) |
| +Glinide | 79 (2.8) | 16 (1.5) | 0 (0.0) | 17 (5.4) | 0 (0.0) | NA | 0 (0.0) | 1 (14.3) | 0 (0.0) |
| +SGLT2i | 256 (9.0) | 128 (11.6) | 11 (3.0) | 2 (0.6) | 7 (6.9) | 2 (4.0) | NA | 0 (0.0) | 2 (25.0) |
| +Insulin | 5 (0.2) | 2 (0.2) | 1 (0.3) | 1 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA | 0 (0.0) |
| +GLP-1 | 0 (0.0) | 16 (1.5) | 2 (0.5) | 2 (0.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | NA |
| MDV database | |||||||||
| Index treatment | DPP-4i | BG | SU | α-GI | TZD | Glinide | SGLT2i | Insulin | GLP-1 |
| Pts with add-on therapy | n=3179 | n=878 | n=342 | n=344 | n=81 | n=74 | n=35 | n=24 | n=12 |
| +DPP-4i | NA | 602 (68.6) | 215 (62.9) | 208 (60.5) | 43 (53.1) | 42 (56.8) | 12 (34.3) | 113 (50.4) | 0 (0.0) |
| +BG | 1168 (36.7) | NA | 51 (14.9) | 36 (10.5) | 14 (17.3) | 7 (9.5) | 12 (34.3) | 26 (11.6) | 4 (33.3) |
| +SU | 736 (23.2) | 44 (5.0) | NA | 36 (10.5) | 3 (3.7) | 1 (1.4) | 4 (11.4) | 10 (4.5) | 4 (33.3) |
| +α-GI | 414 (13.0) | 38 (4.3) | 29 (8.5) | NA | 6 (7.4) | 15 (20.3) | 0 (0.0) | 28 (12.5) | 1 (8.3) |
| +TZD | 168 (5.3) | 29 (3.3) | 13 (3.8) | 4 (1.2) | NA | 4 (5.4) | 0 (0.0) | 1 (0.4) | 0 (0.0) |
| +Glinide | 189 (5.9) | 9 (1.0) | 0 (0.0) | 26 (7.6) | 2 (2.5) | NA | 0 (0.0) | 12 (5.4) | 0 (0.0) |
| +SGLT2i | 190 (6.0) | 94 (10.7) | 7 (2.0) | 5 (1.5) | 8 (9.9) | 0 (0.0) | NA | 2 (0.9) | 3 (25.0) |
| +Insulin | 239 (7.5) | 35 (4.0) | 14 (4.1) | 19 (5.5) | 1 (1.2) | 3 (4.1) | 1 (2.9) | NA | 0 (0.0) |
| +GLP-1 | 2 (0.1) | 10 (1.1) | 4 (1.2) | 1 (0.3) | 0 (0.0) | 1 (1.4) | 4 (11.4) | 0 (0.0) | NA |
‘+’ indicates add-on therapy with new antidiabetic drug class.
α-GI, α-glucosidase inhibitor; BG, biguanide; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1 receptor agonist; JMDC, Japan Medical Data Center; MDV, Medical Data Vision; NA, not applicable; pts, patients; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione; UT, untreated.